We are a major European venture capital firm. We are a leading life sciences investor financing highly innovative companies worldwide. We provide biotech ventures with the resources to develop novel therapies for indications with high unmet medical needs. We are united by our commitment to achieving success for new, promising companies. We invest in companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. We invest globally in biotech ventures, focusing exclusively on innovative therapeutic drugs. Ysios Capital was founded in 2008 and has offices in San Sebastian and Barcelona. With more than €400M AUM, we are the largest life sciences venture capital firm in Spain, with our investment successes providing a significant boost to the country’s biotech sector.
San Sebastián, Spain
Founded in 2008
11-50 Employees
Working industry
Finance and Insurance
Type of company
Service provider
Ownership structure
Privately Held
Locations
2 Locations
Number of products
6 Products
Number of services
2 Services
Specialised areas
Asset Management, Finance, Financial Services
Ysios Capital offers a wide range of products and services
Product
LAVA Therapeutics Presents Preclinical Data – Ysios Capital
Go to product >
Product
Galecto Announces Pricing of Initial Public Offering – Ysios Capital
Go to product >
Product
New Clinical Data from Aura Biosciences – Ysios Capital
Go to product >
Service
Sanifit Appoints Adam Levy as Chief Financial Officer – Ysios Capital
Go to product >
Product
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation – Ysios Capital
Go to product >
Product
CorWave Receives 2017 Deloitte ‘Technology Fast 50 Biotech of the Future’ Award of the Parisian Region – Ysios Capital
Go to product >
Service
AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team – Ysios Capital
Go to product >
Product
Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ – Ysios Capital
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
Spain
Overall risk estimation:
Very low
The ESG Data of countries are based on public sources
Environment
A
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Get insights into the use cases of Ysios Capital
Use case
Kala pharmaceuticals announces new drug application for inveltystm (kpi-121 1%) has been accepted for review by the u.s. Food and drug administration – Ysios Capital
INVELTYS expected to be the first twice-daily ocular steroid indicated for the treatment of inflammation and pain following ocular surgery, if approved PDUFA target action date of August 24, 2018 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 5, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating
Use case
MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding – Ysios Capital
Initiative Aimed at New Clinical Applications for Optical Coherence Tomography March 25, 2014 07:00 AM Eastern Daylight Time MADRID--(BUSINESS WIRE)– MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, today announced the kick off of a three-year initiative to translate the latest OCT research into new clinical applications. Called the “BiopsyPen
Ysios Capital operates in 1 country around the world
Get an overview of the locations of Ysios Capital
Location
Country
State
City
Headquarter
Spain
Autonomous Community of the Basque Country
San Sebastián
Oficina Barcelona
Spain
Catalonia
Barcelona
Some frequent questions that have been asked about Ysios Capital
Where is Ysios Capital located?
The company headquarter of Ysios Capital is located in San Sebastián, Autonomous Community of the Basque Country, Spain. Ysios Capital has subsidiaries in Spain
How many employees does Ysios Capital approximately have?
As of the latest available information Ysios Capital has around 11-50 employees worldwide.
When was Ysios Capital founded?
Ysios Capital was founded in 2008
In which industries does Ysios Capital mainly work?
The company Ysios Capital has it's main focus in the industries of Finance and Insurance
Check out some interesting alternative companies to Ysios Capital
Pivotal bioVenture Partners
San Francisco, United States
1-10 Employees
2017
Established in 2017, we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe. We specialize in venture building in the life sciences industry, partnering with innovative healthcare companies in the Greater China region. We focus on capturing investment opportunities with publicly traded life sciences companies that are looking to scale and grow.
Nan Fung Life Sciences
San Francisco, United States
1-10 Employees
2017
Established in 2017, we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe. We specialize in venture building in the life sciences industry, partnering with innovative healthcare companies in the Greater China region. We focus on capturing investment opportunities with publicly traded life sciences companies that are looking to scale and grow.
Vesalius Biocapital III
Luxembourg
11-50 Employees
2007
We are investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Vesalius Biocapital is a European life sciences venture capital investor. Our portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.
V-Bio Ventures
Ghent, Belgium
1-10 Employees
2015
We are a life sciences Venture Capital fund that helps transform scientific innovation into products that positively impact people’s lives. Our extensive network and expertise in the sector allow us to contribute more than just capital. We look for innovative and transformational technologies with high societal and/or environmental impact potential, in line with the U.N. We focus on therapeutics, diagnostics supporting medical therapies, and sustainable agriculture. Part of the companies we back are built on VIB-derived innovations.
Kurma Partners
Paris, France
11-50 Employees
2009
We provide capital/funding to the companies we have founded with our funds and invite other investors to join us. We are also involved in early stage companies that have already been created, but always by supporting their development by providing our expertise and network. We have built a strong network of partners with the best European academic research players, to transform their disruptive scientific discoveries into cutting-edge medicines or medical devices to diagnose and treat patients with severe diseases with high unmet medical need. Our ambition is to work with leading European research centers to build the healthcare industry of tomorrow. Because of our business, we are players in the world of healthcare and as such are committed to making our contribution to sustainable development.
Two River
New York, United States
1-10 Employees
2004
We are uniquely positioned to understand and balance the needs of the investment and life science communities. We provide capital, operational capability, corporate development and transaction support and leadership recruitment and mentorship to accelerate the pace of research and clinical development. Each of our investments is a unique partnership, often working closely with founding teams on product development, regulatory and corporate strategy as well as day-to-day business operations.
